Breakthrough in Bladder Cancer Treatment: New Study on Small Cell Carcinoma

Strategic Insights -

A rare and aggressive form of bladder cancer, small cell carcinoma, has been the focus of a recent study published in Future Oncology. According to the research, treatment regimens for this cancer are often derived from small cell lung cancer (SCLC) literature, with platinum and etoposide commonly used in the first-line setting. Despite these treatments, responses are generally short-lived, and patients often relapse, highlighting the need for more effective later lines of therapy.

Key Takeaways:

  • Small cell carcinoma of the bladder is a rare and aggressive malignancy, accounting for less than 1% of all bladder malignancies.
  • Treatment regimens for this cancer are often derived from small cell lung cancer (SCLC) literature, with platinum and etoposide commonly used in the first-line setting.
  • Lurbinectedin, an alkylating agent, has been approved for use in patients with SCLC, and immune checkpoint inhibitors have also been approved for SCLC, improving survival when added to chemotherapy.
  • The study aims to investigate the efficacy of lurbinectedin with or without avelumab in small cell carcinoma of the bladder.
  • Phase II trials are underway to evaluate the combination of lurbinectedin and avelumab in patients with small cell carcinoma of the bladder.
  • The research was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Jazz Pharmaceuticals, and EMD Serono Research & Development Institute, Inc.

Statistics:

  • Less than 1% of all bladder malignancies are small cell carcinoma of the bladder.
  • Platinum and etoposide are commonly used in the first-line setting for treatment of small cell carcinoma of the bladder.
  • 1263 is the supplement number for the news report in Immunotherapy Weekly, July 16, 2025.

Sources:

  • A Phase Ii Study of Lurbinectedin With or Without Avelumab In Small Cell Carcinoma of the Bladder (Laser)-design and Rationale. Future Oncology, 2025;21(10):1171-1177.
  • NewsRx. Recent Findings from National Cancer Institute (NCI) Has Provided New Information about Bladder Cancer [A Phase Ii Study of Lurbinectedin With or Without Avelumab In Small Cell Carcinoma of the Bladder (Laser)-design and Rationale]. Immunotherapy Weekly. July 16, 2025; p 1263.